Calcipotriene

Summary

Calcipotriene (CHEMBL1200666) is an approved small-molecule antipsoriatic (ATC D05AX02) targeting VDR; indicated across 12 conditions including psoriasis and acne.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D05AX02 (+1 more)
• Targets: 1 (VDR)
• Indications: 12 conditions
• Clinical trials: 81
• Chemistry: 412.6 Da · C27H40O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200666
Name	Calcipotriene
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5288783
ChEBI	CHEBI:50749
ATC	D05AX02, D05AX52
Molecular formula	C27H40O3
Molecular weight	412.6
InChIKey	LWQQLNNNIPYSNX-UROSTWAQSA-N

SMILES: C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C

IUPAC name: trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

ChEBI definition: A seco-cholestane that is 26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene carrying additional hydroxy substituents at positions 1, 3 and 24. It is used (as its hydrate) in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients.

Pharmacological roles (ChEBI): antipsoriatic, drug allergen.

Also known as: Calcipotriene, Calcipotriene component of enstilar, Calcipotriene component of taclonex, Calcipotriene component of wynzora, Calcipotriene hydrate, Calcipotriene monohydrate, Calcipotriol, Calcipotriol anhydrous, Calcipotriol hydrate, Calcipotriol monohydrate, Calciptriol, Dovobet

Patent coverage: 5,476 distinct patent families (21,689 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
VDR	Vitamin D receptor	Agonist	9.3	0.2%	P11473

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Vitamin D3 receptor, Progesterone receptor, 5-hydroxytryptamine receptor 1A, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Adenosine receptor A3, Androgen receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
VDR	9.51	Kd	0.31	nM	CHEMBL_ACT_276997
Q63921	5.66	AC50	2200	nM	CHEMBL_ACT_25174988
NR1I2	5.17	AC50	6800	nM	CHEMBL_ACT_25188608
PTGS2	5.02	AC50	9600	nM	CHEMBL_ACT_25166769

Target pathways

Aggregated over 1 target gene(s): VDR.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Vitamin D (calciferol) metabolism	1	VDR
Nuclear Receptor transcription pathway	1	VDR
SUMOylation of intracellular receptors	1	VDR

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
cell morphogenesis	1
skeletal system development	1
calcium ion transport	1
intracellular calcium ion homeostasis	1
lactation	1
negative regulation of cell population proliferation	1
positive regulation of gene expression	1
negative regulation of keratinocyte proliferation	1
cell differentiation	1
positive regulation of bone mineralization	1
intracellular receptor signaling pathway	1
phosphate ion transmembrane transport	1
nuclear receptor-mediated bile acid signaling pathway	1
mRNA transcription by RNA polymerase II	1

Indications & clinical

Indications

12 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676
acne	2	MONDO:0011438	EFO:0003894
atopic eczema	2	MONDO:0004980	EFO:0000274
skin disorder	2	MONDO:0005093	EFO:0000701
actinic keratosis	2	MONDO:0005173	EFO:0002496
radiodermatitis	2	MONDO:0043771	MONDO:0043771
vitiligo	1	MONDO:0008661	EFO:0004208
scleroderma	1	MONDO:0019340	EFO:1001993
localized scleroderma	1	MONDO:0019562	EFO:1001361
squamous cell carcinoma	0	MONDO:0005096	EFO:0000707

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 81.

Phase distribution

Phase	Trials
PHASE4	17
PHASE2	13
PHASE1	13
Not specified	12
PHASE3	11
EARLY_PHASE1	6
PHASE2/PHASE3	5
PHASE1/PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03827876	PHASE4	RECRUITING	Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT04372277	PHASE4	RECRUITING	Taltz in Combination With Enstilar for Psoriasis
NCT05185258	PHASE4	ACTIVE_NOT_RECRUITING	Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07453238	PHASE4	NOT_YET_RECRUITING	Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
NCT00437255	PHASE4	COMPLETED	Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
NCT00608777	PHASE4	TERMINATED	Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
NCT01745133	PHASE4	COMPLETED	Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
NCT02004574	PHASE4	COMPLETED	Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris
NCT02858713	PHASE4	COMPLETED	Adherence in Topical Treatment of Psoriasis
NCT03080545	PHASE4	COMPLETED	Enstilar in Combination With Biologic Agents
NCT03441789	PHASE4	COMPLETED	Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
NCT03848871	PHASE4	COMPLETED	The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
NCT04227288	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
NCT04555707	PHASE4	UNKNOWN	The Maintenance Effect of Enstilar Foam in Combination With Otezla
NCT04571151	PHASE4	UNKNOWN	Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis
NCT06329258	PHASE4	COMPLETED	Combination of Sotyktu and Enstilar for Plaque Psoriasis
NCT05381597	PHASE2/PHASE3	RECRUITING	5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
NCT06851507	PHASE3	RECRUITING	A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses
NCT00279162	PHASE3	COMPLETED	Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis
NCT00574249	PHASE3	COMPLETED	Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
NCT00670241	PHASE3	COMPLETED	Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris
NCT00691002	PHASE3	COMPLETED	Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
NCT01139580	PHASE3	COMPLETED	The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
NCT01188928	PHASE3	COMPLETED	LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
NCT01445886	PHASE2/PHASE3	COMPLETED	Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
NCT01694433	PHASE2/PHASE3	COMPLETED	Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy
NCT01763424	PHASE2/PHASE3	COMPLETED	Nicotinamide in the Treatment of Psoriasis
NCT02644954	PHASE3	UNKNOWN	Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis
NCT03331523	PHASE3	COMPLETED	To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
NCT03731091	PHASE3	COMPLETED	To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
NCT04071106	PHASE2/PHASE3	UNKNOWN	Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial
NCT05174598	PHASE3	COMPLETED	A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
NCT05699603	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
NCT07410793	PHASE2	RECRUITING	Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.
NCT00392067	PHASE2	COMPLETED	LEO19123 Cream in the Treatment of Atopic Dermatitis
NCT00404196	PHASE2	COMPLETED	LEO19123 Cream in the Treatment of Hand Eczema
NCT00445250	PHASE2	UNKNOWN	The Role of Calcipotriol as Radioprotector of Skin
NCT00578370	PHASE1/PHASE2	COMPLETED	Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test
NCT00796211	PHASE2	COMPLETED	A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

Molecule	Source	Status	Shared targets
CALCITRIOL	ChEMBL	Phase 4 (approved)	VDR
CHOLECALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
DOXERCALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
TACALCITOL	ChEMBL	Phase 4 (approved)	VDR
CURCUMIN	ChEMBL	Phase 3	VDR
MAXACALCITOL	ChEMBL	Phase 3	VDR
SEOCALCITOL	ChEMBL	Phase 3	VDR
TAUROLITHOCHOLIC ACID	ChEMBL	Phase 3	VDR
chenodiol	PubChem	Approved	VDR